Genzyme Expects Fabrazyme Approval Before Confirmatory Trial Completion
Executive Summary
Genzyme expects to receive FDA approval for its Fabry disease therapy Fabrazyme prior to the January 2004 completion of a confirmatory efficacy study
You may also be interested in...
Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval
Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call
Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval
Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call
TKT Replagal Surrogate Data Should Be Reworked For Accelerated Approval
Transkaryotic Therapeutics' Replagal histologic data should be reevaluated to determine whether they may satisfy a surrogate endpoint for accelerated approval in Fabry Disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 14